ARC-EX System
Commercial- Indications
- Spinal cord injury, Upper limb movement disorders
Company intelligence / Profile preview
ONWARD Medical’s pivotal Up-LIFT trial of the non-invasive ARC–EX® system met primary safety and effectiveness endpoints. In the study, 90% of participants with chronic incomplete tetraplegia improved strength or function in their upper limbs. Significant improvements were also seen in sensory scores and quality of life measures. The company has submitted a De Novo application to the FDA for clearance of its first device.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ONWARD Medical.